clarithromycin has been researched along with sitafloxacin in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Hamasuna, R; Jensen, JS; Osada, Y | 1 |
| Hakanen, AJ; Huovinen, P; Kotilainen, P; Lehtopolku, M; Nakari, UM; Siitonen, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Sano, C; Sato, K; Shimizu, T; Tomioka, H | 1 |
| Fukuhara, S; Hibi, T; Hirata, K; Matsuzaki, J; Nishizawa, T; Okada, S; Saito, Y; Suzuki, H; Tsugawa, H | 1 |
| Furuta, T; Ichikawa, H; Kodaira, C; Nishino, M; Osawa, S; Sahara, S; Sugimoto, K; Sugimoto, M; Umemura, K; Uotani, T; Watanabe, H; Yamada, T; Yamade, M | 1 |
| Hayakawa, Y; Hirata, Y; Koike, K; Sakitani, K; Serizawa, T; Shichijo, S; Suzuki, N; Yamada, A | 1 |
| Irie, K; Kaneko, H; Kondo, M; Maeda, S; Sasaki, T; Shibata, W; Sue, S | 1 |
| Arai, Y; Fujimoto, Y; Handoh, T; Ihara, H; Kurokawa, K; Miida, T; Misawa, S; Naito, T; Nakamura, A; Ochi, Y; Okabe, T; Shibayama, K; Sumiyoshi, I; Tabe, Y; Takahashi, K; Takei, S; Togo, S; Watanabe, J | 1 |
2 trial(s) available for clarithromycin and sitafloxacin
| Article | Year |
|---|---|
Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; Fluoroquinolones; Gastritis; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Time Factors; Treatment Outcome | 2014 |
Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Gastritis; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Sulfonamides; Treatment Failure; Treatment Outcome | 2019 |
8 other study(ies) available for clarithromycin and sitafloxacin
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
Topics: Microbial Sensitivity Tests; Mycoplasma genitalium; Polymerase Chain Reaction | 2009 |
Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
Topics: Anti-Bacterial Agents; Campylobacter coli; Campylobacter Infections; Campylobacter jejuni; Carbapenems; Drug Resistance, Multiple, Bacterial; Erythromycin; Feces; Finland; Humans; Macrolides; Microbial Sensitivity Tests; Minocycline; Tigecycline | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Antimicrobial activities of clarithromycin, gatifloxacin and sitafloxacin, in combination with various antimycobacterial drugs against extracellular and intramacrophage Mycobacterium avium complex.
Topics: Anti-Infective Agents; Cell Line; Clarithromycin; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Fluoroquinolones; Gatifloxacin; Humans; Macrophages; Microbial Sensitivity Tests; Mycobacterium avium Complex | 2002 |
Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Proteins; Biomarkers, Pharmacological; Clarithromycin; DNA Gyrase; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Mutation; Treatment Failure | 2012 |
Efficacy of triple therapy with esomeprazole, amoxicillin, and sitafloxacin as a third-line Helicobacter pylori eradication regimen.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Metronidazole; Middle Aged; Prospective Studies; Treatment Outcome | 2016 |
The synergetic effect of sitafloxacin-arbekacin combination in the Mycobacterium abscessus species.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Humans; Microbial Sensitivity Tests; Mycobacterium; Mycobacterium abscessus; Mycobacterium Infections, Nontuberculous | 2023 |